Singapore: +65-85097465 | India: +91-40-42023318
  U.S / Canada Toll Free: +1-866-259-4781
  Zimbabwe: +263-735539685, 773876488


Clinical Trial News

Love may be the cure for drunkenness

Oxytocin is a hormone that plays a role in social and sexual behavior. Now, in a rat study, researchers have found that oxytocin also appears to prevent alcohol intoxication.

ESPERITE (Euronext ESP) pioneers first treatment worldwide of Cerebral Palsy using two types of stem cells

The clinical trial aims to demonstrate safety and preliminary efficacy of sequential intravenous infusion of the ex vivo expanded mesenchymal stem cells (MSC) derived from cord tissue and the cord...

Baricitinib superior to placebo in reducing rheumatoid arthritis disease activity in second Phase 3 study

Eli Lilly and Company and Incyte Corporation have announced that the investigational medicine baricitinib demonstrated a statistically significant improvement compared to placebo in a second...

Inflectra (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Data have been presented today on the use of Hospira's Inflectra (infliximab), the world's first approved biosimilar monoclonal antibody (mAb), at the European Crohn's and Colitis Organisation...

Development of personalized cellular therapy for brain cancer

Preclinical study results pave the way for newly opened clinical trial of immune cells engineered to attack protein found on tumors in 30 percent of patients with glioblastomaImmune cells...

'Precision medicine' model may help prevent diabetes in at-risk population

New research published in The BMJ details the development of a 'precision medicine' model that could predict the best ways to prevent diabetes in those at high risk.

Statins may not protect against Parkinson's after all, study finds

Some previous studies have suggested that statins offer protective benefits against Parkinson's. However, a new study suggests statins may actually increase Parkinson's risk.

Significant findings in U.S. National Institutes of Health's trial of pluristem's PLX-R18 cells for treatment of acute radiation syndrome

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, has announced the positive results of a recently completed trial conducted by the U.S.

James Lind Institute Newsletter
James Lind Institute Linkedin
James Lind Institute RSS
James Lind Institute Email Update
James Lind Institute Blog
James Lind Institute Facebook